Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.

Dario TrapaniKiu Tay-TeoMegan E TeschFelipe RoitbergManju SengarSara C AltunaMichael J HassettArmando A GenazzaniAaron S KesselheimCurigliano Giuseppe

Published in: Current oncology (Toronto, Ont.) (2022)

A lack of robust efficacy-safety data is a central problem for conducting HTA of cancer medicines, potentially resulting in misinformed resource allocation.

Keyphrases

electronic health record
healthcare
big data
public health
papillary thyroid
palliative care
mental health
study protocol
phase iii
squamous cell
risk assessment
young adults
phase ii
human health